The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 3.36 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.75 — no flag raisedOK
- Earnings quality 74/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as MAXCYTE, INC. reports it. History and quarterly detail are in the app.
- Product$18.7M
- License$12.4M
- Assay And Other Service Revenue$2.0M
Leadership changes
From MAXCYTE, INC.'s own filings, the day they're filed.
- Parmeet Ahuja · Chief Financial Officer · appointmenteff. 2026-03-30
- Ali Soleymannezhad · Chief Commercial Officer · departureeff. 2025-08-11
- Art Mandell · Directors · departureeff. 2024-12-31
Latest filings
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-06-16
- 10-Q · Quarterly report2026-05-13
- 8-K · Company announcement2026-05-12
- DEF 14A · Annual proxy (pay & governance)2026-04-29
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about MAXCYTE, INC., every answer cited🔒
- The Intelligence Brief — added when MAXCYTE, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.